Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Innomed Technologies Inc. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data indicates there are 2 pending office actions currently active. This count represents the volume of outstanding regulatory responses required for the company's pending applications in the biotechnology sector.
The prosecution of these matters involves 2 distinct examiners and is localized within 1 distinct art unit. Because the work is restricted to 1 distinct art unit, the company's legal strategy is focused on a specific technical classification at the patent office. The involvement of 2 distinct examiners means that each pending action is being handled by a different individual, requiring the company to manage separate prosecution timelines.
TAYLOR, MARISSA ENVENESIA is the busiest examiner for this portfolio, with 1 busiest examiner pending office action. This specific examiner is responsible for 1 of the 2 pending office actions currently identified in the data. Consequently, the company must address the requirements of 2 distinct examiners to resolve the pending office actions currently affecting their Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYLOR, MARISSA ENVENESIA | 1 | 78.6% | +31.6% |
| WELLES, COLMAN THOMAS | 1 | 29.2% | +64.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18306099 | FORMULATIONS CONTAINING ERYTHRITOL AND COMBINATION SKIN THERAPIES | WELLES, COLMAN THOMAS | 5d |
| 18912446 | PRECISION DISPENSING | TAYLOR, MARISSA ENVENESIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18306099 | FORMULATIONS CONTAINING ERYTHRITOL AND COMBINATION SKIN THERAPIES | WELLES, COLMAN THOMAS | 5d |
| 18912446 | PRECISION DISPENSING | TAYLOR, MARISSA ENVENESIA | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18912446 | PRECISION DISPENSING | TAYLOR, MARISSA ENVENESIA | — | §102§103 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18306099 | FORMULATIONS CONTAINING ERYTHRITOL AND COMBINATION SKIN THERAPIES | WELLES, COLMAN THOMAS | 1612 | §103Other | Final Rejection | 5d | Pending | Apr 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial